Cash, cash equivalents and marketable securities totaled $322.5 million at June 30, 2026; the company repurchased $49.4 million of shares by Aug. 4.
Key catalysts include an Aug. 25, 2026 FDA PDUFA date for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, tied to a potential $250 million U.S. milestone.
Management said 2H 2026 could strengthen cash flow with the planned Theravance Biopharma acquisition, expected to close in 2H 2026 and add YUPELRI cash flows.
Zymeworks posts wider Q2 loss as revenue falls
Zymeworks posted a GAAP net loss of $45.02 million in Q2 2026, swinging from net income of $2.32 million a year earlier; revenue fell to $4.59 million.
Operating loss widened to $42.18 million as operating expenses eased to $46.77 million, led by R&D expense of $27.44 million.
ZYME•
